Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index; 27 of the 131 sources its claims cite were checked for support.

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer

Open access

Abstract

Guideline article describing standard treatment strategies for colorectal cancer and summarizing evidence-based recommendations.

Overview

CoChat Summary

TL;DR

The JSCCR Guidelines 2016 present consensus-based standard treatment strategies for colorectal cancer in Japan, covering endoscopic and surgical treatment, chemotherapy, radiotherapy, palliative care, and surveillance. They use literature review, GRADE-style evidence assessment, and Delphi consensus to issue recommendations for clinical questions.

Key findings

  • Colorectal cancer mortality in Japan surpassed 49,000 in 2015, and deaths per unit population increased approximately tenfold over the past 50 years.
  • After curative resection of pStage 0–III colorectal cancer, 5-year survival rates by site were: all sites 82.2%, colon 83.8%, rectosigmoid 81.7%, and Ra–Rb rectum 79.3% (patients treated 2000–2004).
  • For rectal cancer with the lower tumor border distal to the peritoneal reflection and invasion beyond the muscularis propria, lateral lymph node metastasis rate was 20.1%; lateral lymph node dissection was expected to reduce intrapelvic recurrence risk by 50% and improve 5-year survival by 8–9%.
  • For pT1 (SM) colorectal cancer, the lymph node metastasis rate was 12.5% when submucosal invasion depth was ≥1000 μm; Stage II postoperative adjuvant chemotherapy was not recommended routinely (recommendation/evidence level 1A), while 6 months was the standard duration for 5-FU-based adjuvant chemotherapy (1A).

Methods

  • These guidelines were prepared by the JSCCR Guideline Committee by consensus, based on literature searches and consideration of the Japanese health insurance system and clinical practice.
  • Literature searches used PubMed and Ichushi-Web from January 2008 to March 2012, with the search period extended to July 2016 for adjuvant chemotherapy and chemotherapy for advanced or recurrent colorectal cancer; 12,000 documents were retrieved (PubMed 7909, Ichushi 4091), and 2320 were selected and critically reviewed.
  • Evidence levels and strength of recommendations were assessed with reference to the GRADE system; recommendation strength was determined by Delphi-method voting, with ≥70% committee consensus required.

Limitations

  • Stated: the guidelines provide only general recommendations and do not control or limit treatment strategies or methods not described; responsibility for treatment outcomes rests with the personnel directly in charge, not the JSCCR or Guideline Committee.
  • Stated: no strength of recommendation was presented in clinical questions, and for several interventions the efficacy and safety were not established, with calls for appropriately planned clinical trials.
  • Evident from the text: recommendations are explicitly framed around the Japanese medical insurance system and actual clinical practice in Japan, and the literature search periods ended in 2012 or 2016, so applicability outside Japan or to later evidence is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s10147-017-1101-6

Cites

286 of 286 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Treatment strategies for cTis (M) cancer and cT1 (SM) cancer
Fig. 1 Treatment strategies for cTis (M) cancer and cT1 (SM) cancerCC BY · PubMed Central
Fig. 2 Surgical treatment strategies for cStage 0 to cStage III colorectal cancer
Fig. 2 Surgical treatment strategies for cStage 0 to cStage III colorectal cancerCC BY · PubMed Central
Fig. 3 Treatment strategies for Stage IV colorectal cancer
Fig. 3 Treatment strategies for Stage IV colorectal cancerCC BY · PubMed Central
Fig. 4 Treatment strategies for recurrent colorectal cancer
Fig. 4 Treatment strategies for recurrent colorectal cancerCC BY · PubMed Central
Fig. 5 Treatment strategies for hematogenous metastases
Fig. 5 Treatment strategies for hematogenous metastasesCC BY · PubMed Central
Fig. 6 Chemotherapy for unresectable colorectal cancer
Fig. 6 Chemotherapy for unresectable colorectal cancerCC BY · PubMed Central
Fig. 7 An example of a surveillance schedule after curative resection of pStage I to pStage III colorectal cancer
Fig. 7 An example of a surveillance schedule after curative resection of pStage I to pStage III colorectal cancerCC BY · PubMed Central
Fig. 8 Graph of the cumulative incidence of recurrence according to stage (project study by the JSCCR: patients in years 1991–1996)
Fig. 8 Graph of the cumulative incidence of recurrence according to stage (project study by the JSCCR: patients in years 1991–1996)CC BY · PubMed Central
Fig. 9 Graph of the cumulative incidence of recurrence according to the site of recurrence (project study by the JSCCR: patients in years 1991–1996)
Fig. 9 Graph of the cumulative incidence of recurrence according to the site of recurrence (project study by the JSCCR: patients in years 1991–1996)CC BY · PubMed Central
Fig. 10 Treatment strategies for pT1 (SM) cancer after endoscopic resection
Fig. 10 Treatment strategies for pT1 (SM) cancer after endoscopic resectionCC BY · PubMed Central
Fig. 11 Method for measuring depth of SM invasion. a When it is possible to identify or estimate the location of the muscularis mucosae, depth of SM invasion is measured from the lower border of the muscularis mucosae. b, c When it is not possible to identify or estimate the location of the muscularis mucosae, depth of SM invasion is measured from the surface layer of the muscularis mucosae. Sessile lesion (b), Pedunculated lesion (c). d For pedunculated lesions with tangled a muscularis mucosae, depth of SM invasion is measured as the distance between the point of deepest invasion and the reference line, which is defined as the boundary between the tumor head and the stalk. e Invasion by pedunculated lesions that is limited to within the head is defined as “head invasion”
Fig. 11 Method for measuring depth of SM invasion. a When it is possible to identify or estimate the location of the muscularis mucosae, depth of SM invasion is measured from the lower border of the muscularis mucosae. b, c When it is not possible to identify or estimate the location of the muscularis mucosae, depth of SM invasion is measured from the surface layer of the muscularis mucosae. Sessile lesion (b), Pedunculated lesion (c). d For pedunculated lesions with tangled a muscularis mucosae, depth of SM invasion is measured as the distance between the point of deepest invasion and the reference line, which is defined as the boundary between the tumor head and the stalk. e Invasion by pedunculated lesions that is limited to within the head is defined as “head invasion”CC BY · PubMed Central
Fig. 12 Venous invasion (arrow in A). A Located in the vicinity of an artery (a). B Elastic fibers in the vein wall have become clear by Victoria blue staining
Fig. 12 Venous invasion (arrow in A). A Located in the vicinity of an artery (a). B Elastic fibers in the vein wall have become clear by Victoria blue stainingCC BY · PubMed Central
Fig. 13 Lymphatic invasion (arrow in a). a A cancer cell nest is visible in the interstitial space. b Double staining for cytokeratin and D2-40. Cancer cells are stained brown, and the lymphatic endothelium is stained purplish red
Fig. 13 Lymphatic invasion (arrow in a). a A cancer cell nest is visible in the interstitial space. b Double staining for cytokeratin and D2-40. Cancer cells are stained brown, and the lymphatic endothelium is stained purplish redCC BY · PubMed Central
Fig. 14 Space formed by artifacts during preparation of the specimen (arrow in a). a A cancer cell nest is visible in the interstitial space. b Double staining for cytokeratin and D2-40. The interstitial space is D2-40-negative
Fig. 14 Space formed by artifacts during preparation of the specimen (arrow in a). a A cancer cell nest is visible in the interstitial space. b Double staining for cytokeratin and D2-40. The interstitial space is D2-40-negativeCC BY · PubMed Central
Fig. 15 Budding (arrow in b). A cancer cell nest consisting of one or fewer than five cells that has infiltrated the interstitium at the invasive margin of the cancer is seen. b is the square area in a
Fig. 15 Budding (arrow in b). A cancer cell nest consisting of one or fewer than five cells that has infiltrated the interstitium at the invasive margin of the cancer is seen. b is the square area in aCC BY · PubMed Central

Verification

Claims the paper makes

14 Valid · 15 Not valid · 52 Not checked · 49 Own results and interpretations

81 more claims · 9 with their cited sources checked

Create a free account to see all 130 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 21
  • The quote only partly states this claim. 3

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

4 of 4

Citations

Cites

Show all 285 references

Research works printed but not linked: 1

  1. Beppu TMT, Maeda K (2000) Microwave coagulation therapy for metastatic liver tumor. Surg Ther 83:237–242

Cited by

See all 2,467

Metadata

Authors
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., Ishihara, S., Kanemitsu, Y., Kawano, H., Kinugasa, Y., Kokudo, N., Murofushi, K., Nakajima, T., Oka, S., Sakai, Y., Tsuji, A., Uehara, K., Ueno, H., Yamazaki, K., Yoshida, M., Yoshino, T., Boku, N., Fujimori, T., Itabashi, M., Koinuma, N., Morita, T., Nishimura, G., Sakata, Y., Shimada, Y., Takahashi, K., Tanaka, S., Tsuruta, O., Yamaguchi, T., Yamaguchi, N., Tanaka, T., Kotake, K., & Sugihara, K.
Affiliations
  • The University of Tokyo (JP)
  • Aichi Cancer Center (JP)
  • Niigata University (JP)
  • National Cancer Center Hospital (JP)
  • Saitama Medical Center, Saitama Medical University (JP)
  • Tokyo Medical and Dental University (JP)
  • St Mary's Hospital (JP)
  • Shizuoka Cancer Center (JP)
  • The Cancer Institute Hospital (JP)
  • St. Marianna University School of Medicine (JP)
  • Kyoto University (JP)
  • Kagawa University (JP)
  • National Defense Medical College (JP)
  • National Cancer Center Hospital East (JP)
  • Shinko Hospital (JP)
  • Tokyo Women's Medical University (JP)
  • Aomori Prefectural Central Hospital (JP)
  • Misawa City Hospital (JP)
  • Tokyo Metropolitan Komagome Hospital (JP)
  • Kurume University (JP)
  • Seirei Sakura Citizen Hospital (JP)
  • Tochigi Cancer Center (JP)
Corresponding author
Watanabe, Toshiaki
Venue
International Journal of Clinical Oncology
Published
2017-03-27
Volume
23
Issue
1
Pages
1-34
ISSN
  • 1341-9625 (ISSN-L)
  • 1437-7772
OpenAlex
W1990423062
Cited by
2,467
References
285
Citations by year
2026: 15 · 2025: 106 · 2024: 243 · 2023: 256 · 2022: 270 · 2021: 343 · 2020: 322 · 2019: 234 · 2018: 144 · 2017: 116
FWCI
98.39
Type
journal article
Language
en
Open access
Locations
  • International Journal of Clinical Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (17K08691, 15K10150, 17K10655)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords
colorectal cancer, treatment guidelines, clinical practice variation, informed consent, classification of evidence, clinical questions, health insurance system, Japan
MeSH terms
Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Japan, Liver Neoplasms, Lymph Node Excision, Laparoscopy, Rectal Neoplasms, Colorectal Neoplasms, Chemotherapy, Adjuvant, Dose Fractionation, Radiation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. https://app.cochat.ai/papers/10.1007/s10147-017-1101-6
The paper
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., Ishihara, S., Kanemitsu, Y., Kawano, H., Kinugasa, Y., Kokudo, N., Murofushi, K., Nakajima, T., Oka, S., Sakai, Y., . . . Sugihara, K. (2018). Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-017-1101-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.